** Medical equipment maker Penumbra PEN.N rise 8.39% to $293.90 in premarket trading
** Revenue rises 10.8% to $315.52 million from a year earlier in fourth quarter; analysts expected $311.52 million, per data compiled by LSEG
** "We expect cash generation to scale nicely in the coming years," analysts at Morgan Stanley say
** J.P.Morgan says "with another year of low-to-mid teens sales growth on tap plus nice margin expansion Penumbra is delivering good fundamental results"
** Of the 19 brokerages covering the stock, at least 14 raised their price targets following the results
** Brokerage Canaccord Genuity raises PT to $340, a Wall Street high, from $323
** Average rating is "buy", with a median PT of $308 - LSEG
** As of last close, stock up ~14% this year; stock fell ~6% in 2024
(Reporting by Joel Jose in Bengaluru)
((joeljose@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。